Loading
M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.
Malignant ascites, fluid that builds up in the abdomen from cancer spread to the peritoneum, is drained repeatedly for symptom relief. Catumaxomab, an EpCAM-CD3 bispecific, was approved in Europe in 2009 for this use and later withdrawn. M701 revives the approach: YZY Biopharma's phase 3 trial in China compares intraperitoneal M701 with paracentesis alone for the time until fluid must be drained again.
1.One arm of M701 binds EpCAM on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"M701" OR ABSTRACT:"M701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about M701, not a curated reading list.
Shares Wuhan YZY Biopharma and the tag pipeline.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares CD3, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares CD3, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares CD3, T-cell engagers (bispecific), Ovarian cancer and the tag pipeline.
Shares Bispecific antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.